ONC vs ZYME

For growth investors, BeOne Medicines Ltd.

(ONC) is the stronger pick with 40. 2% revenue growth year-over-year, versus 38. 9% for Zymeworks Inc. (ZYME). BeOne Medicines Ltd. (ONC) offers the better valuation at 9. 5x trailing P/E (51. 3x forward), making it the more compelling value choice. Analysts rate BeOne Medicines Ltd. (ONC) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Zymeworks Inc.

is actually cheaper at 23. 3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, BeOne Medicines Ltd.

(ONC) delivered a total return of -0. 2%, compared to -6. 4% for Zymeworks Inc. (ZYME). Over 10 years, the gap is even starker: ONC returned +1094% versus ZYME's +112. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BeOne Medicines Ltd.

(ONC) is the lower-risk stock at 0. 70β versus Zymeworks Inc. 's 0. 97β — meaning ZYME is approximately 39% more volatile than ONC relative to the S&P 500. On balance sheet safety, Zymeworks Inc. (ZYME) carries a lower debt/equity ratio of 7% versus 46% for BeOne Medicines Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BeOne Medicines Ltd.

(ONC) is pulling ahead at 40. 2% versus 38. 9% for Zymeworks Inc. (ZYME). On earnings-per-share growth, the picture is similar: BeOne Medicines Ltd. grew EPS 637. 4% year-over-year, compared to 33. 3% for Zymeworks Inc.. Over a 3-year CAGR, ONC leads at 55. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

BeOne Medicines Ltd.

(ONC) is the more profitable company, earning 5. 4% net margin versus -76. 6% for Zymeworks Inc. — meaning it keeps 5. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ONC leads at 8. 4% versus -87. 3% for ZYME. At the gross margin level — before operating expenses — ZYME leads at 89. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Zymeworks Inc.

(ZYME) trades at 23. 3x forward P/E versus 51. 3x for BeOne Medicines Ltd. — 28. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ZYME: 38. 8% to $38. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, BeOne Medicines Ltd.

(ONC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 70), +1094% 10Y return). Both have compounded well over 10 years (ONC: +1094%, ZYME: +112. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.